MiDROPS® Achieves Pivotal Milestone: Proven Safe and Effective in Phase II Clinical Trial
OKLAHOMA CITY--(BUSINESS WIRE)--EyeCRO is thrilled to announce that groundbreaking data from the first clinical application of its innovative MiDROPS® platform technology is being presented by Telios Pharma at the 96th meeting of the Association for Research in Vision and Ophthalmology meeting in Seattle, WA. The presentation entitled, “TL-925, a First-in-Class, Topical, Bruton’s Tyrosine Kinase Inhibitor in Subjects with Moderate to Severe Dry Eye Disease” (Poster 2965 – A0124), demonstrated M